Safety and effect of topical recombinant human interleukin‐1β in the management of pressure sores

M. C. Robson, A. Abdullah, B. F. Burns, Linda Phillips, L. Garrison, W. Cowan, D. Hill, J. Vandeberg, L. E. Robson, S. Scheeler

Research output: Contribution to journalArticle

28 Scopus citations

Abstract

Interleukin‐1β is produced by numerous cell types including monocytes and fibroblasts. It has been shown to stimulate multiple cell types including fibroblasts, keratinocytes, endothelial cells, neutrophils, macrophages, and lymphocytes. Previously, interleukin‐1β was shown to accelerate healing in partial‐thickness and full‐thickness wounds in animals and was also shown to be safe when applied topically in Phase I human trials. Therefore a prospectively randomized, blind, placebo‐controlled trial was performed with patients with chronic pressure ulcers. Doses of interleukin‐1β of .01 µg, .10 µg, and 1.0 µg per square centimeter did not show acceleration of healing of the pressure ulcers. Therefore use of recombinant human interleukin‐1β in this study was safe but, at the dose levels tested, did not result in improvement in the healing ratio.

Original languageEnglish (US)
Pages (from-to)177-181
Number of pages5
JournalWound Repair and Regeneration
Volume2
Issue number3
DOIs
StatePublished - 1994

ASJC Scopus subject areas

  • Surgery
  • Dermatology

Fingerprint Dive into the research topics of 'Safety and effect of topical recombinant human interleukin‐1β in the management of pressure sores'. Together they form a unique fingerprint.

  • Cite this

    Robson, M. C., Abdullah, A., Burns, B. F., Phillips, L., Garrison, L., Cowan, W., Hill, D., Vandeberg, J., Robson, L. E., & Scheeler, S. (1994). Safety and effect of topical recombinant human interleukin‐1β in the management of pressure sores. Wound Repair and Regeneration, 2(3), 177-181. https://doi.org/10.1046/j.1524-475X.1994.20307.x